Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A; ADhere Investigators. Simpson EL, et al. Among authors: ferrucci s. JAMA Dermatol. 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534. JAMA Dermatol. 2023. PMID: 36630140 Free PMC article. Clinical Trial.
Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe.
Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taïeb A; PO-SCORAD Investigators Group. Stalder JF, et al. Allergy. 2011 Aug;66(8):1114-21. doi: 10.1111/j.1398-9995.2011.02577.x. Epub 2011 Mar 18. Allergy. 2011. PMID: 21414011
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study.
Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, Girolomoni G, Naldi L, Ferrucci SM. Pezzolo E, et al. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e11-e13. doi: 10.1111/jdv.19382. Epub 2023 Aug 1. J Eur Acad Dermatol Venereol. 2024. PMID: 37483150 No abstract available.
Emerging Systemic Treatments for Atopic Dermatitis.
Ferrucci SM, Tavecchio S, Marzano AV, Buffon S. Ferrucci SM, et al. Dermatol Ther (Heidelb). 2023 May;13(5):1071-1081. doi: 10.1007/s13555-023-00920-4. Epub 2023 Apr 18. Dermatol Ther (Heidelb). 2023. PMID: 37072648 Free PMC article. Review.
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.
Stingeni L, Chiricozzi A, Calzavara-Pinton P, Napolitano M, Peris K, Schena D, Patruno C, Rossi M, Foti C, Fargnoli MC, Corazza M, Ferrucci SM, Pigatto PD, Romanelli M, Fabbrocini G, Girolomoni G, Passante M, Romita P, Esposito M, Schettini N, Marzano AV, Tonini G, Marietti R, Casciola G, Argenziano G, Hansel K; AtopyReg® study group. Stingeni L, et al. Am J Clin Dermatol. 2024 Jan;25(1):149-160. doi: 10.1007/s40257-023-00819-y. Epub 2023 Sep 19. Am J Clin Dermatol. 2024. PMID: 37725229 Free PMC article.
169 results